Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

NCT ID: NCT07090161

Last Updated: 2026-01-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-15

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Uncontrolled Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental/Iloperidone

Group Type EXPERIMENTAL

iloperidone

Intervention Type DRUG

iloperidone

Placebo Comparator

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo comparator

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

iloperidone

iloperidone

Intervention Type DRUG

Placebo

placebo comparator

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fanapt

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* SiSBP \>/= 130 mmHg despite \>8 weeks treatment w/ 1 or more antihypertensive therapies

Exclusion Criteria

* Confirmed Grade 3/severe hypertension (SiSBP \>/= 180 mmHg, SiDBP \>/= 120 mmHg), unstable cardiac disease, renal insufficiency
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vanda Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vanda Investigative Site

Phoenix, Arizona, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

Tempe, Arizona, United States

Site Status RECRUITING

Vanda Investigative Site

Tucson, Arizona, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

Chula Vista, California, United States

Site Status RECRUITING

Vanda Investigative Site

Dublin, California, United States

Site Status RECRUITING

Vanda Investigative Site

Valencia, California, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

Walnut Creek, California, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

Doral, Florida, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

Fort Myers, Florida, United States

Site Status RECRUITING

Vanda Investigative Site

Columbus, Georgia, United States

Site Status RECRUITING

Vanda Investigative Site

Oak Brook, Illinois, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

Tinley Park, Illinois, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

El Dorado, Kansas, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

Wichita, Kansas, United States

Site Status RECRUITING

Vanda Investigative Site

Lexington, Kentucky, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

Hazelwood, Missouri, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

Las Vegas, Nevada, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

Mount Kisco, New York, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

Rochester, New York, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

Kinston, North Carolina, United States

Site Status RECRUITING

Vanda Investigative Site

Cincinnati, Ohio, United States

Site Status RECRUITING

Vanda Investigative Site

Norman, Oklahoma, United States

Site Status RECRUITING

Vanda Investigative Site

Oklahoma City, Oklahoma, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

Charleston, South Carolina, United States

Site Status RECRUITING

Vanda Investigative Site

Carrollton, Texas, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

Salt Lake City, Utah, United States

Site Status NOT_YET_RECRUITING

Vanda Investigative Site

Burke, Virginia, United States

Site Status RECRUITING

Vanda Investigative Site

Norfolk, Virginia, United States

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Vanda Pharmaceuticals, Inc.

Role: CONTACT

202-734-3400

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VP-VYV-683-2401

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Obese Hypertension Study (0954-315)
NCT00289887 COMPLETED PHASE3
SER100 in Isolated Systolic Hypertension
NCT01987284 COMPLETED PHASE2